Individualizing Treatment With SGLT-2 Inhibitor Therapy in Type 2 Diabetes Mellitus

被引：0
|
作者：
Miller, Eden M.
机构：
来源：
JOURNAL OF FAMILY PRACTICE | 2017年 / 66卷 / 02期
关键词：
CARDIOVASCULAR OUTCOMES; POOLED ANALYSIS; SAFETY; EMPAGLIFLOZIN; ROSIGLITAZONE; TOLERABILITY; ASSOCIATION; MANAGEMENT; STATEMENT; EVENTS;
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：S13 / S16
页数：4
相关论文
共 50 条
  • [41] TYPE 2 DIABETES MELLITUS IN 2010 Individualizing treatment targets in diabetes care
    Buse, John B.
    NATURE REVIEWS ENDOCRINOLOGY, 2011, 7 (02) : 67 - 68
  • [42] Expect the Unexpected: SGLT-2 Inhibitors in the Treatment of Type 2 Diabetes and/or Heart Failure
    Seferovic, Jelena P.
    Seferovic, Petar M.
    CARDIOLOGY, 2020, 145 (05) : 321 - 323
  • [43] EFFICACY OF SGLT-2 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES: SINGLE CENTRE EXPERIENCE
    Cakmak, Ramazan
    Oghyanous, Golpouneh Alizad
    Selcukbiricik, Ozlem Soyluk
    Karsidag, Kubilay
    JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, 2025, 88 (01): : 45 - 52
  • [44] The effect of sglt-2 inhibitor dapagliflozin on adropin serum levels in patients with chronic heart failure and concomitant type 2 diabetes mellitus
    Berezin, A.
    Fuschtey, I. M.
    Berezin, A. A.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [45] Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes
    Siegmund, Thorsten
    Javier Ampudia-Blasco, Francisco
    Schnell, Oliver
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 162
  • [46] DAPAGLIFLOZIN, AN SGLT2 INHIBITOR FOR THE TREATMENT OF TYPE 2 DIABETES
    Demaris, K. M.
    White, J. R.
    DRUGS OF TODAY, 2013, 49 (05) : 289 - 301
  • [47] Efficacy and Safety of Triple Therapy with SGLT-2 Inhibitor, DPP-4 Inhibitor, and Metformin in Type 2 Diabetes: A Meta-Analysis
    Li, Mengdi
    Wang, Sining
    Wang, Xiaoli
    ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 2023, 29 (05) : 320 - 326
  • [48] Effects of the SGLT-2 inhibitor empagliflozin on vascular function and central haemodynamics in patients with type 2 diabetes
    Schmieder, R. E.
    Striepe, K.
    Jumar, A.
    Karg, M. V.
    Kannenkeril, D.
    Schneider, M. P.
    Ott, C.
    DIABETOLOGIA, 2017, 60 : S417 - S417
  • [49] Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes
    Dziuba, J.
    Alperin, P.
    Racketa, J.
    Iloeje, U.
    Goswami, D.
    Hardy, E.
    Perlstein, I.
    Grossman, H. L.
    Cohen, M.
    DIABETES OBESITY & METABOLISM, 2014, 16 (07): : 628 - 635
  • [50] A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
    Jung, Chang Hee
    Jang, Jung Eun
    Park, Joong-Yeol
    DIABETES & METABOLISM JOURNAL, 2014, 38 (04) : 261 - 273
12345